Use of Molecular Genetic Analyses in Danish Routine Newborn Screening

Historically, the analyses used for newborn screening (NBS) were biochemical, but increasingly, molecular genetic analyses are being introduced in the workflow. We describe the application of molecular genetic analyses in the Danish NBS programme and show that second-tier molecular genetic testing is useful to reduce the false positive rate while simultaneously providing information about the precise molecular genetic variant and thus informing therapeutic strategy and easing providing information to parents. When molecular genetic analyses are applied as second-tier testing, valuable functional data from biochemical methods are available and in our view, such targeted NGS technology should be implemented when possible in the NBS workflow. First-tier NGS technology may be a promising future possibility for disorders without a reliable biomarker and as a general approach to increase the adaptability of NBS for a broader range of genetic diseases, which is important in the current landscape of quickly evolving new therapeutic possibilities. However, studies on feasibility, sensitivity, and specificity are needed as well as more insight into what views the general population has towards using genetic analyses in NBS. This may be sensitive to some and could have potentially negative consequences for the NBS programme.

[1]  T. Battelino,et al.  Next-Generation Sequencing in Newborn Screening: A Review of Current State , 2021, Frontiers in Genetics.

[2]  J. Loeber,et al.  [Neonatal screening in Europe revisited: An ISNS-perspective on the current state and developments since 2010]. , 2021, Medecine sciences : M/S.

[3]  S. Grünert,et al.  Health Outcomes of Infants With Vitamin B12 Deficiency Identified by Newborn Screening and Early Treated. , 2021, The Journal of pediatrics.

[4]  J. Vockley,et al.  Impact of newborn screening on the reported incidence and clinical outcomes associated with medium- and long-chain fatty acid oxidation disorders , 2021, Genetics in Medicine.

[5]  S. Grünert,et al.  Newborn screening and disease variants predict neurological outcome in isovaleric aciduria , 2021, Journal of inherited metabolic disease.

[6]  H. Levy.  Ethical and Psychosocial Implications of Genomic Newborn Screening , 2021, International journal of neonatal screening.

[7]  G. la Marca,et al.  Development of Strategies to Decrease False Positive Results in Newborn Screening , 2020, International journal of neonatal screening.

[8]  M. Durkin,et al.  Translating Molecular Technologies into Routine Newborn Screening Practice , 2020, International journal of neonatal screening.

[9]  Dona M. Kanavy,et al.  Variant Classification Concordance using the ACMG-AMP Variant Interpretation Guidelines across Nine Genomic Implementation Research Studies. , 2020, American journal of human genetics.

[10]  J. Merritt,et al.  Considering Proximal Urea Cycle Disorders in Expanded Newborn Screening , 2020, International journal of neonatal screening.

[11]  Aashish N. Adhikari,et al.  The role of exome sequencing in newborn screening for inborn errors of metabolism , 2020, Nature Medicine.

[12]  S. Ferdinandusse,et al.  Performance of Expanded Newborn Screening in Norway Supported by Post-Analytical Bioinformatics Tools and Rapid Second-Tier DNA Analyses , 2020, International journal of neonatal screening.

[13]  P. Bross,et al.  Riboflavin Deficiency—Implications for General Human Health and Inborn Errors of Metabolism , 2020, International journal of molecular sciences.

[14]  R. Zetterström,et al.  Expanded Screening of One Million Swedish Babies with R4S and CLIR for Post-Analytical Evaluation of Data , 2020, International journal of neonatal screening.

[15]  P. Rinaldo,et al.  The Combined Impact of CLIR Post-Analytical Tools and Second Tier Testing on the Performance of Newborn Screening for Disorders of Propionate, Methionine, and Cobalamin Metabolism , 2020, International journal of neonatal screening.

[16]  Ayesha Ahmad,et al.  Incorporation of Second-Tier Biomarker Testing Improves the Specificity of Newborn Screening for Mucopolysaccharidosis Type I , 2020, International journal of neonatal screening.

[17]  D. Hougaard,et al.  Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years , 2020, Pediatric pulmonology.

[18]  D. Hougaard,et al.  Danish expanded newborn screening is a successful preventive public health programme. , 2020, Danish medical journal.

[19]  D. Grafham,et al.  Next Generation Sequencing in Newborn Screening in the United Kingdom National Health Service , 2019, International journal of neonatal screening.

[20]  Kiely N. James,et al.  A Randomized, Controlled Trial of the Analytic and Diagnostic Performance of Singleton and Trio, Rapid Genome and Exome Sequencing in Ill Infants. , 2019, American journal of human genetics.

[21]  D. Viskochil,et al.  Genotype‐phenotype relationships in mucopolysaccharidosis type I (MPS I): Insights from the International MPS I Registry , 2019, Clinical genetics.

[22]  M. Hiligsmann,et al.  Newborn screening for SMA in Southern Belgium , 2019, Neuromuscular Disorders.

[23]  E. Parens,et al.  On What We Have Learned and Still Need to Learn about the Psychosocial Impacts of Genetic Testing. , 2019, The Hastings Center report.

[24]  John Reynders,et al.  Diagnosis of genetic diseases in seriously ill children by rapid whole-genome sequencing and automated phenotyping and interpretation , 2019, Science Translational Medicine.

[25]  G. Kollberg,et al.  Mitochondrial complex IV deficiency caused by a novel frameshift variant in MT-CO2 associated with myopathy and perturbed acylcarnitine profile , 2018, European Journal of Human Genetics.

[26]  E. Parens,et al.  Sequencing Newborns: A Call for Nuanced Use of Genomic Technologies. , 2018, The Hastings Center report.

[27]  M. Baumgartner,et al.  Newborn screening: A disease‐changing intervention for glutaric aciduria type 1 , 2018, Annals of neurology.

[28]  V. Sutton,et al.  Newborn screening: a review of history, recent advancements, and future perspectives in the era of next generation sequencing , 2016, Current opinion in pediatrics.

[29]  Madhuri Hegde,et al.  Variants of uncertain significance in newborn screening disorders: implications for large-scale genomic sequencing , 2016, Genetics in Medicine.

[30]  T. Rootwelt,et al.  Implementation of newborn screening for cystic fibrosis in Norway. Results from the first three years. , 2016, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[31]  M. Daly,et al.  High-Quality Exome Sequencing of Whole-Genome Amplified Neonatal Dried Blood Spot DNA , 2016, PloS one.

[32]  John J. Mitchell,et al.  The health system impact of false positive newborn screening results for medium-chain acyl-CoA dehydrogenase deficiency: a cohort study , 2016, Orphanet Journal of Rare Diseases.

[33]  H. Yoon,et al.  Screening newborns for metabolic disorders based on targeted metabolomics using tandem mass spectrometry , 2015, Annals of pediatric endocrinology & metabolism.

[34]  Avni Santani,et al.  Actionable exomic incidental findings in 6503 participants: challenges of variant classification , 2015, Genome research.

[35]  T. Sokolsky,et al.  Development of DNA Confirmatory and High-Risk Diagnostic Testing for Newborns Using Targeted Next-Generation DNA Sequencing , 2014, Genetics in Medicine.

[36]  K. Bhattacharya,et al.  Expanded newborn screening in New South Wales: missed cases , 2014, Journal of Inherited Metabolic Disease.

[37]  Piero Rinaldo,et al.  Postanalytical tools improve performance of newborn screening by tandem mass spectrometry , 2014, Genetics in Medicine.

[38]  J. Vissing,et al.  Recurrent myoglobinuria and deranged acylcarnitines due to a mutation in the mtDNA MT-CO2 gene , 2013, Neurology.

[39]  Flemming Skovby,et al.  Biochemical screening of 504,049 newborns in Denmark, the Faroe Islands and Greenland--experience and development of a routine program for expanded newborn screening. , 2012, Molecular genetics and metabolism.

[40]  D. Hougaard,et al.  MCAD deficiency in Denmark. , 2012, Molecular genetics and metabolism.

[41]  Y. Li,et al.  Psychological Effects of False-Positive Results in Expanded Newborn Screening in China , 2012, PLoS ONE.

[42]  M. Murray.  Genetic Screening of Prospective Parents , 2011 .

[43]  J. Abdenur,et al.  Maple syrup urine disease: further evidence that newborn screening may fail to identify variant forms. , 2010, Molecular genetics and metabolism.

[44]  J. Till,et al.  Bloodspot acylcarnitine and amino acid analysis in cord blood samples: efficacy and reference data from a large cohort study , 2009, Journal of Inherited Metabolic Disease.

[45]  J. Fletcher,et al.  Newborn screening for 3‐methylcrotonyl‐CoA carboxylase deficiency: population heterogeneity of MCCA and MCCB mutations and impact on risk assessment , 2006, Human mutation.

[46]  S. Waisbren,et al.  Expanded Newborn Screening for Biochemical Disorders: The Effect of a False-Positive Result , 2006, Pediatrics.

[47]  Edwin W. Naylor,et al.  Effect of Expanded Newborn Screening for Biochemical Genetic Disorders on Child Outcomes and Parental Stress , 2003 .

[48]  I Knudsen,et al.  Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. , 2001, American journal of human genetics.

[49]  L. D. Schroeder,et al.  Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. , 1999, American journal of human genetics.

[50]  G. Lynch,et al.  Maple Syrup Urine Disease , 1964, Journal of mental deficiency research.

[51]  D. Hougaard,et al.  Abnormal Newborn Screening in a Healthy Infant of a Mother with Undiagnosed Medium-Chain Acyl-CoA Dehydrogenase Deficiency. , 2015, JIMD reports.

[52]  D. Hougaard,et al.  Normal Levels of Plasma Free Carnitine and Acylcarnitines in Follow-Up Samples from a Presymptomatic Case of Carnitine Palmitoyl Transferase 1 (CPT1) Deficiency Detected Through Newborn Screening in Denmark. , 2012, JIMD reports.

[53]  R. Hegele,et al.  patient-oriented and epidemiological research Carnitine palmitoyltransferase IA polymorphism P479L is common in Greenland Inuit and is associated with elevated plasma apolipoprotein A-I , 2009 .

[54]  L. Waddell,et al.  Medium-chain acyl-CoA dehydrogenase deficiency: genotype-biochemical phenotype correlations. , 2006, Molecular genetics and metabolism.